Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625703 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00625703 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT00625703, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.
Interventions
- DRUG Linezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625703
The ClinicalTrials.gov registry entry for NCT00625703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linezolid is the first listed.
NCT00625703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625703 about?
NCT00625703 is a clinical study titled "Pharmacokinetics of Linezolid in Children With Cystic Fibrosis". To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.
What is the current status of trial NCT00625703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2010-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00625703?
The interventions under investigation include: Linezolid (DRUG).
Who is sponsoring clinical trial NCT00625703?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.